Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03833440
Title Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Assistance Publique Hopitaux De Marseille

lung non-small cell carcinoma


Ceralasertib + Durvalumab

Durvalumab + Oleclumab


Durvalumab + Monalizumab

Age Groups: adult | senior
Covered Countries FRA

No variant requirements are available.